331 related articles for article (PubMed ID: 33620087)
1. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.
Yamagishi Y; Sasaki N; Nakano Y; Matushita Y; Omura T; Shimizu S; Saito K; Kobayashi K; Narita Y; Kondo A; Shiokawa Y; Nagane M; Ichimura K
Cancer Sci; 2021 Nov; 112(11):4702-4710. PubMed ID: 34523186
[TBL] [Abstract][Full Text] [Related]
3. The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.
Hiemcke-Jiwa LS; Minnema MC; Radersma-van Loon JH; Jiwa NM; de Boer M; Leguit RJ; de Weger RA; Huibers MMH
Hematol Oncol; 2018 Apr; 36(2):429-435. PubMed ID: 29210102
[TBL] [Abstract][Full Text] [Related]
4. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Kitano Y; Maeda S; Motomura K; Aoki K; Takeuchi K; Nagata Y; Hattori H; Tsujiuchi T; Motomura A; Nishikawa T; Kibe Y; Shinjo K; Kondo Y; Saito R
Cancer Sci; 2023 Jun; 114(6):2544-2551. PubMed ID: 36859777
[TBL] [Abstract][Full Text] [Related]
5. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Kusakabe M; Nanmoku T; Suehara Y; Matsuoka R; Noguchi M; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Muratani M; Hasegawa Y; Chiba S
Cancer Sci; 2019 Jan; 110(1):401-407. PubMed ID: 30353605
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma.
De Luca A; Antinori A; Cingolani A; Larocca LM; Linzalone A; Ammassari A; Scerrati M; Roselli R; Tamburrini E; Ortona L
Br J Haematol; 1995 Aug; 90(4):844-9. PubMed ID: 7669663
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Suehara Y; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Hasegawa Y; Chiba S
Cancer Sci; 2018 Jan; 109(1):225-230. PubMed ID: 29151258
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
[TBL] [Abstract][Full Text] [Related]
10. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract][Full Text] [Related]
12. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
[TBL] [Abstract][Full Text] [Related]
14. Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma.
Bravetti C; Degaud M; Armand M; Sourdeau E; Mokhtari K; Maloum K; Osman J; Verrier P; Houillier C; Roos-Weil D; Soussain C; Choquet S; Hoang-Xuan K; Le Garff-Tavernier M; Denis JA; Davi F
Br J Haematol; 2023 Jun; 201(6):1088-1096. PubMed ID: 36941788
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
[TBL] [Abstract][Full Text] [Related]
16. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
[TBL] [Abstract][Full Text] [Related]
17.
Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
[TBL] [Abstract][Full Text] [Related]
18. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
Baraniskin A; Kuhnhenn J; Schlegel U; Chan A; Deckert M; Gold R; Maghnouj A; Zöllner H; Reinacher-Schick A; Schmiegel W; Hahn SA; Schroers R
Blood; 2011 Mar; 117(11):3140-6. PubMed ID: 21200023
[TBL] [Abstract][Full Text] [Related]
19. Detection of the
Zorofchian S; Lu G; Zhu JJ; Duose DY; Windham J; Esquenazi Y; Ballester LY
Front Oncol; 2018; 8():382. PubMed ID: 30294590
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
